CY1123790T1 - Σημασμενοι me 18f αναστολεις του ειδικου προστατικου αντιγονου της μεμβρανης (psma) και χρηση τους ως απεικονιστικα μεσα για τον καρκινο του προστατη - Google Patents

Σημασμενοι me 18f αναστολεις του ειδικου προστατικου αντιγονου της μεμβρανης (psma) και χρηση τους ως απεικονιστικα μεσα για τον καρκινο του προστατη

Info

Publication number
CY1123790T1
CY1123790T1 CY20211100081T CY211100081T CY1123790T1 CY 1123790 T1 CY1123790 T1 CY 1123790T1 CY 20211100081 T CY20211100081 T CY 20211100081T CY 211100081 T CY211100081 T CY 211100081T CY 1123790 T1 CY1123790 T1 CY 1123790T1
Authority
CY
Cyprus
Prior art keywords
prostate
psma
inhibitors
specific membrane
membrane antigen
Prior art date
Application number
CY20211100081T
Other languages
English (en)
Inventor
Jens CARDINALE
Martin Schäfer
Klaus Kopka
Matthias Eder
Ulrike Bauder-Wuest
Michael Eisenhut
Martina Benesova
Uwe Haberkorn
Frederik L. Giesel
Original Assignee
Deutsches Krebsforschungszentrum
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deutsches Krebsforschungszentrum filed Critical Deutsches Krebsforschungszentrum
Publication of CY1123790T1 publication Critical patent/CY1123790T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61Halogen atoms or nitro radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465Nicotine; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/03Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/041Heterocyclic compounds
    • A61K51/044Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002Heterocyclic compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02Linear peptides containing at least one abnormal peptide link
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57434Specifically defined cancers of prostate
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Η παρούσα εφεύρεση γενικά σχετίζεται με το πεδίο των ραδιοφαρμακευτικών προϊόντων και την χρήση τους στην πυρηνική ιατρική ως ιχνηθέτες και απεικονιστικά μέσα για διάφορες καταστάσεις νόσου του καρκίνου του προστάτη.
CY20211100081T 2015-09-30 2021-02-01 Σημασμενοι me 18f αναστολεις του ειδικου προστατικου αντιγονου της μεμβρανης (psma) και χρηση τους ως απεικονιστικα μεσα για τον καρκινο του προστατη CY1123790T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP15002800 2015-09-30
EP16164090 2016-04-06
EP16182764 2016-08-04
PCT/EP2016/001573 WO2017054907A1 (en) 2015-09-30 2016-09-19 18f-tagged inhibitors of prostate specific membrane antigen (psma) and their use as imaging agents for prostate cancer

Publications (1)

Publication Number Publication Date
CY1123790T1 true CY1123790T1 (el) 2022-05-27

Family

ID=57121178

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20211100081T CY1123790T1 (el) 2015-09-30 2021-02-01 Σημασμενοι me 18f αναστολεις του ειδικου προστατικου αντιγονου της μεμβρανης (psma) και χρηση τους ως απεικονιστικα μεσα για τον καρκινο του προστατη

Country Status (32)

Country Link
US (3) US10815200B2 (el)
EP (2) EP3356385B1 (el)
JP (1) JP6824971B2 (el)
KR (1) KR102233726B1 (el)
CN (1) CN108026144B (el)
AU (1) AU2016333334B2 (el)
BR (1) BR112018005899A2 (el)
CA (1) CA2996330A1 (el)
CL (1) CL2018000604A1 (el)
CO (1) CO2018003726A2 (el)
CU (1) CU24524B1 (el)
CY (1) CY1123790T1 (el)
DK (1) DK3356385T3 (el)
EA (1) EA037512B1 (el)
ES (1) ES2844586T3 (el)
GE (1) GEP20207106B (el)
HR (1) HRP20210183T1 (el)
HU (1) HUE053064T2 (el)
IL (1) IL258378B (el)
LT (1) LT3356385T (el)
MX (1) MX2018004050A (el)
MY (1) MY197061A (el)
NZ (1) NZ739770A (el)
PE (1) PE20181350A1 (el)
PH (1) PH12018500701A1 (el)
PL (1) PL3356385T3 (el)
RS (1) RS61394B1 (el)
SA (1) SA518391121B1 (el)
SI (1) SI3356385T1 (el)
TN (1) TN2018000089A1 (el)
WO (1) WO2017054907A1 (el)
ZA (1) ZA201801024B (el)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3497108A1 (en) 2016-08-10 2019-06-19 Cancer Targeted Technology LLC Chelated psma inhibitors
DE102016122273B4 (de) 2016-11-18 2018-06-21 Abx Advanced Biochemical Compounds Gmbh Präkursoren für die Radiofluorierung
JP7167021B2 (ja) * 2016-11-23 2022-11-08 キャンサー ターゲテッド テクノロジー エルエルシー アルブミン結合psma阻害剤
CN110272468B (zh) * 2019-05-14 2020-12-08 上海益泰医药科技有限公司 一种前列腺特异性膜抗原小分子抑制剂及其放射性核素配合物的制备及应用
CN111253465A (zh) * 2020-03-03 2020-06-09 复旦大学附属肿瘤医院 一种psma结合剂及其用途
CA3206250A1 (en) 2021-02-08 2022-08-11 Mark RIJPKEMA Psma-targeting ligands for multimodal applications
CN118265718A (zh) 2021-07-30 2024-06-28 国立大学法人大阪大学 放射性标记化合物及其用途
EP4397322A1 (en) * 2021-09-01 2024-07-10 Tianjin Hengrui Medicine Co., Ltd. Inhibitor of prostate specific membrane antigen and pharmaceutical use thereof

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6479470B1 (en) 1999-04-28 2002-11-12 Georgetown University Ligands for metabotropic glutamate receptors and inhibitors of NAALAdase
CA2451188A1 (en) 2001-06-25 2003-01-03 Drug Innovation & Design, Incorporated Exponential pattern recognition based cellular targeting, compositions, methods and anticancer applications
ATE443260T1 (de) 2002-01-10 2009-10-15 Univ Johns Hopkins Kontrastmittel und verfahren zum imaging von naaldase oder psma
WO2006093991A1 (en) 2005-03-02 2006-09-08 The Cleveland Clinic Foundation Compounds which bind psma and uses thereof
CA2668197A1 (en) 2006-11-03 2008-05-15 Philip S. Low Ex vivo flow cytometry method and device
PL2097111T3 (pl) 2006-11-08 2016-01-29 Molecular Insight Pharm Inc Heterodimery kwasu glutaminowego
CN101568352B (zh) 2007-01-11 2013-08-21 免疫医学股份有限公司 用于蛋白质、肽和其他分子的改进的f-18标记的方法和组合物
EP2136788B1 (en) 2007-03-30 2011-10-26 Bind Biosciences, Inc. Cancer cell targeting using nanoparticles
EP3466928A1 (en) 2007-06-26 2019-04-10 The Johns Hopkins University Labeled inhibitors of prostate-specific membrane antigen (psma), biological evaluation, and use as imaging agents
PL2187965T3 (pl) * 2007-08-17 2020-05-18 Purdue Research Foundation Koniugaty wiążący psma ligand-łącznik i sposoby ich zastosowania
US9422234B2 (en) 2007-11-30 2016-08-23 The Johns Hopkins University Prostate specific membrane antigen (PSMA) targeted nanoparticles for therapy of prostate cancer
EP2240171B1 (en) 2008-01-09 2014-08-13 Molecular Insight Pharmaceuticals, Inc. Inhibitors of carbonic anhydrase IX
HUE059436T2 (hu) 2008-08-01 2022-11-28 Univ Johns Hopkins PSMA-kötõ szerek és alkalmazásaik
WO2010065899A2 (en) 2008-12-05 2010-06-10 Molecular Insight Pharmaceuticals, Inc. Technetium-and rhenium-bis(heteroaryl)complexes and methods of use thereof
EP2389361B1 (en) * 2008-12-05 2016-08-24 Molecular Insight Pharmaceuticals, Inc. Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereof for inhibiting psma
US9056841B2 (en) 2009-03-19 2015-06-16 The Johns Hopkins University PSMA-targeting compounds and uses thereof
GB0905438D0 (en) * 2009-03-30 2009-05-13 Ge Healthcare Ltd Radiolabelling reagents and methods
EP2338892A1 (en) * 2009-12-18 2011-06-29 Bayer Schering Pharma Aktiengesellschaft Prostate specific membrane antigen inhibitors
GB201020314D0 (en) 2010-12-01 2011-01-12 Ge Healthcare Ltd Apoptosis pet imaging agents
US9687572B2 (en) 2010-12-06 2017-06-27 Molecular Insight Pharmaceuticals, Inc. PSMA-targeted dendrimers
WO2012166923A2 (en) 2011-05-31 2012-12-06 Bind Biosciences Drug loaded polymeric nanoparticles and methods of making and using same
WO2013022797A1 (en) 2011-08-05 2013-02-14 Molecular Insight Pharmaceuticals Radiolabeled prostate specific membrane antigen inhibitors
US10011632B2 (en) * 2011-08-22 2018-07-03 Siemens Medical Solutions Usa, Inc. PSMA imaging agents
CA2896571C (en) 2012-12-28 2017-11-21 Blend Therapeutics, Inc. Targeted conjugates encapsulated in particles and formulations thereof
US9889199B2 (en) 2013-02-15 2018-02-13 Case Western Reserve University PSMA ligands and uses thereof
WO2015004029A1 (en) 2013-07-08 2015-01-15 Technische Universität München 18f-labeling of aromatic and heteroaromatic molecules with unprotected carboxylic acid groups
US10406246B2 (en) 2013-10-17 2019-09-10 Deutsches Kresbsforschungszentrum Double-labeled probe for molecular imaging and use thereof
US20150110814A1 (en) 2013-10-18 2015-04-23 Psma Development Company, Llc Combination therapies with psma ligand conjugates
EP4374924A2 (en) * 2013-10-18 2024-05-29 Novartis AG Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
AU2014348601A1 (en) 2013-11-14 2016-05-26 Endocyte, Inc. Compounds for positron emission tomography
US11124845B2 (en) 2014-03-18 2021-09-21 The Johns Hopkins University PSMA-based molecular-genetic reporter system
US10683272B2 (en) 2014-05-06 2020-06-16 The Johns Hopkins University Metal/radiometal-labeled PSMA inhibitors for PSMA-targeted imaging and radiotherapy
EP3183236B1 (en) 2014-08-24 2022-04-20 Max-Planck-Gesellschaft zur Förderung der Wissenschaften Method for the production of 18f-labeled active esters and their application exemplified by the preparation of a psma-specific pet-tracer
EP3193914B1 (en) 2014-09-08 2021-01-20 Molecular Insight Pharmaceuticals, Inc. Organ protection in psma-targeted radionuclide therapy of prostate cancer
EP3011976A1 (en) 2014-10-20 2016-04-27 Deutsches Krebsforschungszentrum 18F-tagged inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents
WO2016062370A1 (en) * 2014-10-20 2016-04-28 Deutsches Krebsforschungszentrum 18f-tagged inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
WO2016065145A2 (en) 2014-10-22 2016-04-28 The Johns Hopkins University Psma targeted reversed carbamates and methods of use thereof

Also Published As

Publication number Publication date
KR102233726B1 (ko) 2021-03-31
KR20180058822A (ko) 2018-06-01
JP6824971B2 (ja) 2021-02-03
CN108026144A (zh) 2018-05-11
AU2016333334A1 (en) 2018-03-08
CL2018000604A1 (es) 2019-03-29
EP3805250A1 (en) 2021-04-14
TN2018000089A1 (en) 2019-07-08
PL3356385T3 (pl) 2021-06-28
CO2018003726A2 (es) 2018-07-19
EP3356385B1 (en) 2020-11-11
MY197061A (en) 2023-05-23
NZ739770A (en) 2019-07-26
EA037512B1 (ru) 2021-04-06
RS61394B1 (sr) 2021-02-26
IL258378A (en) 2018-05-31
GEP20207106B (en) 2020-05-11
PE20181350A1 (es) 2018-08-22
SA518391121B1 (ar) 2021-05-30
CU24524B1 (es) 2021-06-08
HRP20210183T1 (hr) 2021-04-30
IL258378B (en) 2021-03-25
US20180194729A1 (en) 2018-07-12
CU20180030A7 (es) 2018-08-06
ZA201801024B (en) 2019-06-26
HUE053064T2 (hu) 2021-06-28
CA2996330A1 (en) 2017-04-06
WO2017054907A1 (en) 2017-04-06
ES2844586T3 (es) 2021-07-22
DK3356385T3 (da) 2021-02-15
BR112018005899A2 (pt) 2018-10-16
PH12018500701A1 (en) 2018-10-15
US20230295092A1 (en) 2023-09-21
LT3356385T (lt) 2021-02-25
EP3356385A1 (en) 2018-08-08
SI3356385T1 (sl) 2021-04-30
MX2018004050A (es) 2018-08-01
US20210053922A1 (en) 2021-02-25
AU2016333334B2 (en) 2019-07-25
JP2018531243A (ja) 2018-10-25
EA201890282A1 (ru) 2018-09-28
US10815200B2 (en) 2020-10-27
CN108026144B (zh) 2022-02-01

Similar Documents

Publication Publication Date Title
CY1123790T1 (el) Σημασμενοι me 18f αναστολεις του ειδικου προστατικου αντιγονου της μεμβρανης (psma) και χρηση τους ως απεικονιστικα μεσα για τον καρκινο του προστατη
MX2021008977A (es) Inhibidores marcados de antigeno prostatico especifico de membrama (psma), su uso como agentes formadores de imagenes y agentes farmaceuticos para el tratamiento de cancer de prostata.
CY1124544T1 (el) Νεες χηλικες ενωσεις γαδολινιου για χρηση στη μαγνητικη τομογραφια
EA201791167A1 (ru) Способы и композиции для мечения радиоактивным изотопомf биологических препаратов
EA201690862A1 (ru) Соединения для позитронно-эмиссионной томографии
DK3347084T3 (da) Aortakanyle til ex vivo-organplejesystem
CR20160270A (es) ANTICUERPOS ANTI-TAU (pS422) HUMANIZADOS Y MÉTODOS DE UTILIZACIÓN
PT4095130T (pt) Inibidores marcados do antígeno de membrana específico da próstata (psma), seu uso como agentes de imagem e agentes farmacêuticos para o tratamento do cancro da próstata
EA202090071A1 (ru) F-меченое соединение для диагностики рака предстательной железы и его применение
AR106243A1 (es) Inhibidores mejorados del antígeno prostático específico de membrana marcados con 18f y su uso como agentes para la adquisición de imágenes para el cáncer de próstata
TH1801001924A (th) ตัวยับยั้งที่ถูกแท็กด้วย 18f ที่ถูกปรับปรุงของแอนติเจนที่เมมเบรนจำเพาะต่อต่อมลูก หมาก (psma) และการใช้พวกมันเป็นสารสร้างภาพสำหรับมะเร็งต่อมลูกหมาก
EA202092495A1 (ru) МОДУЛЯТОРЫ Cot И СПОСОБЫ ИХ ПРИМЕНЕНИЯ